The Centers for Disease Control and Prevention is currently tracking the rise of another COVID-19 subspecies known as BN.1, and the latest new Omicron offspring will spread nationwide this fall, according to figures released by the agency this month. indicates that there is
About 4.3% of new COVID-19 cases nationwide are now associated with the BN.1 variant, according to ‘Nowcast’. Estimate Released by the CDC on Friday.
The prevalence of new strains is greatest in the western part of the region spanning Arizona, California, Hawaii and Nevada. 6.2% of new cases in that region, HHS Region 9, are from BN.1.
News of new variants nationwide new pace Hospitalizations for COVID-19, which had been declining since September, have started to rise again in the past few weeks.
CDC officials said on Saturday hosted webinars BN.1 is estimated to be doubling nationwide nearly every two weeks, according to the Infectious Diseases Association of America, but warns that early estimates remain vague.
CDC’s Natalie Thornberg said, “The uncertainty in that doubling time is a little higher because of the lower absolute number of sequences, lower proportions, and much larger confidence intervals.
Scientists first designated strain BN.1 back in septemberfrom descendants of the BA.2.75 subspecies found in Europe and Asia.
Some BN.1 strains carry mutations that can cause ‘advanced immune escape’. according to Forecasts from a tool designed by Bloom Lab at Fred Hutchinson Cancer Center.
All BN.1 strains carry a change called the R346T substitution, which Thornburg says is “found in many circulating viruses today.” Its mutation to the spike protein of SARS-CoV-2 was able to stop An important drug used to protect people with weakened immune systems.
BQ.1, BQ.1.1, and XBB
BN.1 joins the crowded field of new Omicron subspecies progeny that has proliferated in recent months,It dominated the case over the summer.
ofThe most popular of the recent new strains. The CDC estimates that nearly half of all infections nationwide are due to one of his two.
Dr. Ashish Jha, the White House COVID-19 officer, told CBS: News in an interview last month.
XBB, another variant that has attracted attention abroad, has yet to reach levels significant enough to warrant being listed as a stand-alone stock in the United States. Thornburg said Saturday that the CDC still estimates XBB at less than 1% nationwide, he said.
However, the CDC variant monitoring By late October, 13% of the samples were from XBB, 30.4% from BQ.1 or BQ.1.1, and none from BN.1.
Findings from Moderna on monday Updated COVID-19 booster shots suggest that new vaccines may offer at least some protection against BQ.1.1.
During Saturday’s webinar, Thornburg said the CDC was also working to publish new real-world data on the efficacy of bivalent injections against the current strain “soon.”
But the rise of new strains threatens to undermine other key tools used to treat and prevent COVID, especially for more vulnerable Americans.
The National Institutes of Health’s COVID-19 Treatment Guidelines Panel warned last week that new variants could evade some COVID-19 treatments, such as Eli Lilly’s monoclonal antibody bebuterobimab. appeal to the clinician Eliminate drug use in areas where these strains were dominant.
This now includes New York and New Jersey areas, where CDC estimates that BQ.1 and BQ.1.1 currently account for the majority of infections.
The rise of these and other evasive Omicron variants also threatens the protection provided by AstraZeneca’s Evusheld, which has been an important tool for protecting immunocompromised Americans, the panel warned. .
Jha said it could take up to six months for companies to develop a new version of the drug to combat the latest variants. He accused Congress of failing to pass funds that could have been subsidized.
“We can’t say we pay through the US government because we don’t have the money and they know it,” Jha said.
https://www.cbsnews.com/news/cdc-now-tracking-bn-1-the-latest-new-covid-variant-on-the-rise/ CDC is now tracking BN.1, the latest new COVID variant on the rise